Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372788 · ClinicalTrials.gov registry record · Phase 2
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00372788: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00372788 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00372788, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed. Treatment will be continued for as long as patients receive clinical benefit.
Interventions
- DRUG Pemetrexed
- DRUG AZD6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00372788 record still lists
NCT00372788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00372788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00372788 about?
NCT00372788 is a clinical study titled "AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen". The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with e...
What is the current status of trial NCT00372788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2006-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00372788?
The interventions under investigation include: Pemetrexed (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00372788?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00372788's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia